Portal de Periódicos da CAPES

Adjuvant Medroxyprogesterone Acetate to Radical Nephrectomy in Renal Cancer: 5-Year Results of a Prospective Randomized Study

1987; Lippincott Williams & Wilkins; Volume: 138; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(17)43647-0

1527-3792

Giorgio Pizzocaro, Luigi Piva, G. Di Fronzo, A Giongo, A. Cozzoli, E Dormia, S. Minervini, A Zanollo, U Fontanella, Giovanni Longo, A. Maggioni,

Bladder and Urothelial Cancer Treatments

No AccessJournal of Urology1 Dec 1987Adjuvant Medroxyprogesterone Acetate to Radical Nephrectomy in Renal Cancer: 5-Year Results of a Prospective Randomized Study Giorgio Pizzocaro, Luigi Piva, Giovanni Di Fronzo, Augusto Giongo, Alberto Cozzoli, Enrico Dormia, Silvano Minervini, Alberto Zanollo, Umberto Fontanella, Giovanni Longo, and Augusto Maggioni Giorgio PizzocaroGiorgio Pizzocaro , Luigi PivaLuigi Piva , Giovanni Di FronzoGiovanni Di Fronzo , Augusto GiongoAugusto Giongo , Alberto CozzoliAlberto Cozzoli , Enrico DormiaEnrico Dormia , Silvano MinerviniSilvano Minervini , Alberto ZanolloAlberto Zanollo , Umberto FontanellaUmberto Fontanella , Giovanni LongoGiovanni Longo , and Augusto MaggioniAugusto Maggioni View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)43647-0AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail From July 1, 1979 to June 30, 1983, 136 consecutive patients from 5 centers in Lombardy entered a prospective randomized study to compare 500mg. adjuvant medroxyprogesterone acetate 3 times a week for 1 year to no treatment following radical nephrectomy for category M0 renal cancer. After a median followup of 5 years (range 42 to 90 months) 40 of 120 evaluable patients (33.3 per cent) experienced relapse after a median interval free of disease of 17 months (range 2 to 74 months). Relapses occurred in 19 of 58 evaluable patients in the adjuvant treatment group (32.7 per cent) and in 21 of the 62 evaluable controls (33.9 per cent). Sex steroid hormone receptors were studied in 102 of the 120 evaluable patients with the dextran-coated charcoal technique. No significant correlation could be found among receptors, relapses and treatment. On the other hand, 33 (56.9 per cent) of the 58 treated patients experienced 39 complications related to the long-term hormonal therapy. Three patients had to discontinue medroxyprogesterone acetate for severe toxicity after 2 to 3 months. Medroxyprogesterone acetate cannot be recommended as adjuvant therapy to radical nephrectomy in patients with renal cell carcinoma. © 1987 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byLenis A, Donin N, Johnson D, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A and Chamie K (2017) Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical TrialsJournal of Urology, VOL. 199, NO. 1, (43-52), Online publication date: 1-Jan-2018.Ljungberg B, Tomić R and Roos G (2018) Deoxyribonucleic Acid Content and Medroxyprogesterone Acetate Treatment in Metastatic Renal Cell CarcinomaJournal of Urology, VOL. 141, NO. 6, (1308-1310), Online publication date: 1-Jun-1989. Volume 138 Issue 6 December 1987 Page: 1379-1381 Advertisement Copyright & Permissions© 1987 by The American Urological Association Education and Research, Inc.Metrics Author Information Giorgio Pizzocaro More articles by this author Luigi Piva More articles by this author Giovanni Di Fronzo More articles by this author Augusto Giongo More articles by this author Alberto Cozzoli More articles by this author Enrico Dormia More articles by this author Silvano Minervini More articles by this author Alberto Zanollo More articles by this author Umberto Fontanella More articles by this author Giovanni Longo More articles by this author Augusto Maggioni More articles by this author Expand All Advertisement PDF downloadLoading ...